New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month, compared with once a week for other obesity drugs like Wegovy and Zepbound that are already on the market.
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Amgen's experimental drug MariTide helped overweight or obese patients lose up to 20% weight on average in a year-long ...
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...
The Wall Street Journal on MSN3h
Eli Lilly and Novo Nordisk’s Obesity Moat Just Got StrongerData from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.
Wall Street Journal on MSN3d
Amgen Obesity Drug Cut Weight In Closely Watched StudyA highly anticipated obesity-drug candidate from biotech Amgen helped patients shed a significant amount of weight in a ...
Key TakeawaysA Phase 2 study of Amgen's experimental weight-loss treatment didn't meet expectations of analysts.Concerns were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback